Ohr Pharmaceutical Inc 4
4 · Ohr Pharmaceutical Inc · Filed Jun 21, 2016
Insider Transaction Report
Form 4
Slakter Jason Scott
Director
Transactions
- Purchase
Common Stock, par value $0.0001 per share
2016-06-20$2.84/sh+5,431$15,424→ 924,489 total - Purchase
Common Stock, par value $0.0001 per share
2016-06-20$2.83/sh+1$3→ 924,490 total - Purchase
Common Stock, par value $0.0001 per share
2016-06-20$2.89/sh+1,700$4,913→ 917,954 total - Purchase
Common Stock, par value $0.0001 per share
2016-06-20$2.71/sh+550$1,491→ 925,040 total - Purchase
Common Stock, par value $0.0001 per share
2016-06-20$2.88/sh+85$245→ 918,039 total - Purchase
Common Stock, par value $0.0001 per share
2016-06-20$2.87/sh+1,019$2,925→ 919,058 total
Holdings
- 697,865(indirect: By LLC)
Common Stock, par value $0.0001 per share
Footnotes (1)
- [F1]SKS Ocular I LLC directly owns the shares of Common Stock. On May 30, 2014, the Issuer completed an ophthalmology assets acquisition of SKS Ocular LLC and SKS Ocular I LLC. Pursuant to the acquisition agreement, among other things, SKS Ocular I LLC is eligible to receive additional shares of Common Stock in three contingent milestone payments. Milestone 1 has been met December 15, 2015, the Issuer issued 497,859 shares of Common Stock to SKS Ocular I LLC. The Reporting Person has investment and voting power with respect to the Common Stock held by SKS Ocular 1 LLC. Therefore, the Reporting Person may be deemed to beneficially own the shares of Common Stock beneficially owned by SKS Ocular 1 LLC. The Reporting Person disclaims any beneficial ownership of the Common Stock directly owed by SKS Ocular I LLC except to the extent of his pecuniary interest therein.